Our proprietary FORCE(TM) platform drives our efforts to develop targeted, modern oligonucleotide therapeutics with the potential to be life-transforming for patients with serious muscle diseases. We designed the FORCE platform using our deep knowledge of muscle biology and oligonucleotide therapeutics to overcome the current limitations in delivery to muscle tissue with the goal of stopping or reversing disease progression. Our initial focus includes programs for myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD).
- force-platform.png (132.48 KiB) Viewed 8847 times
https://www.youtube.com/watch?v=fZr06ANX5cA
Oxana Beskrovnaya, Ph.D., Dyne’s chief scientific officer